Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Van Cutsem E, et al. Among authors: tempero ma. J Clin Oncol. 2020 Sep 20;38(27):3185-3194. doi: 10.1200/JCO.20.00590. Epub 2020 Jul 24. J Clin Oncol. 2020. PMID: 32706635 Free PMC article. Clinical Trial.
Systemic therapy for pancreatic cancer.
Ko AH, Tempero MA. Ko AH, et al. Among authors: tempero ma. Semin Radiat Oncol. 2005 Oct;15(4):245-53. doi: 10.1016/j.semradonc.2005.06.001. Semin Radiat Oncol. 2005. PMID: 16183478 Review.
Treatment of metastatic pancreatic cancer.
Ko AH, Tempero MA. Ko AH, et al. Among authors: tempero ma. J Natl Compr Canc Netw. 2005 Sep;3(5):627-36. doi: 10.6004/jnccn.2005.0036. J Natl Compr Canc Netw. 2005. PMID: 16194454 Review.
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. Verslype C, et al. Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10. doi: 10.1093/annonc/mdm210. Ann Oncol. 2007. PMID: 17600091 Free article.
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. Ko AH, et al. Among authors: tempero ma. Invest New Drugs. 2008 Oct;26(5):463-71. doi: 10.1007/s10637-008-9127-2. Epub 2008 Apr 1. Invest New Drugs. 2008. PMID: 18379729 Clinical Trial.
272 results